Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 312-318

  Al Taei, Saly ^a   Salimu, Josephine ^a   Lester, Jason F ^b   Linnane, Seamus ^c,d   Goonewardena, Madusha ^e   Harrop, Richard ^e   Mason, Malcolm D ^a   Tabi, Zsuzsanna ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d Blackrock Clinic Ireland   (Ireland)

^e OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

5T4; Cancer vaccine; Malignant pleural mesothelioma; Novel target; T cell killing; Tumour associated antigen

Indexed keywords

CD200 ANTIGEN; HLA A2 ANTIGEN; MESOTHELIN; ONCOFETAL ANTIGEN; ONCOFETAL ANTIGEN 5T4; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

ANTIBODIES; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; PLEURAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84863775264     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.008     Document Type: Article

References (30)

1. Vogelzang N., Rusthoven J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
2. Anraku M., Cunningham K.S., Yun Z., Tsao M.S., Zhang L., Keshavjee S., et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008, 135:823-829.
3. + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010, 59:1543-1549.
4. Robinson B., Robinson C., Lake R. Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 2001, 32:197-201.
5. Hegmans J., Hemmes A., Aerts J., Hoogsteden H., Lambrecht B. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005, 171:1168-1177.
6. Sterman D., Haas A., Moon E., Recio A., Schwed D., Vachani A., et al. A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Resp Crit Care Med 2011, 184:1395-1399.
7. Hegmans J., Veltman J., Lambers M., de Vries I., Figdor C., Hendriks R., et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181:1383-1390.
8. Hassan R., Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44:46-53.
9. Ordonez N. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003, 16:192-197.
10. Hole N., Stern P. A 72kDa trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988, 57:239-246.
11. Southall P., Boxer G., Bagshawe K., Hole N., Bromley M., Stern P. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990, 61:89-95.
12. Carsberg C., Myers K., Stern P. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996, 68:84-92.
13. Southgate T., McGinn O., Castro F., Rutkowski A., Al-Muftah M., Marinov G., et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One 2010, 5:e9982.
14. Naganuma H., Kono K., Mori Y., Takayoshi S., Stern P., Tasaka K., et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002, 22:1033-1038.
15. Boghaert E., Sridharan L., Khandke K., Armellino D., Ryan M., Myers K., et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol 2008, 32:221-234.
16. Shaw D., Connolly N., Patel P., Kilany S., Hedlund G., Nordle O., et al. A Phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 2007, 96:567-574.
17. ®) in colorectal, renal, and prostate cancer patients. J Immunother 2010, 33:999-1005.
18. ®) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009, 32:765-772.
19. Shingler W., Chikoti P., Kingsman S., Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008, 20:1057-1066.
20. + T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001, 258:111-126.
21. Tabi Z., Moutaftsi M., Borysiewicz L.K. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol 2001, 166:5695-5703.
22. ®, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccine 2010, 6:12-19.
23. Wrigley E., McGown A., Rennison J., Swindell R., Crowther D., Starzynska T., et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995, 5:269-274.
24. Damelin M., Geles K., Follettie M., Yuan P., Baxter M., Golas J., et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011, 71:4236-4246.
25. Smyth L., Elkord E., Taher T., Jiang H., Burt D., Clayton A., et al. CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006, 119:1638-1647.
26. Thomas K., Smith K., Youde S., Evans M., Fiander A., Borysiewicz L., et al. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int J Cancer 2008, 122:2791-2799.
27. Thiery J., Dorothée G., Haddada H., Echchakir H., Richon C., Stancou R., et al. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 2003, 170:5919-5926.
28. Noman M., Buart S., Van Pelt J., Richon C., Hasmim M., Leleu N., et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009, 182:3510-3521.
29. Eyles J., Puaux A., Wang X., Toh B., Prakash C., Hong M., et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010, 120:2030-2039.
30. Jasani B., Coleman S., Butchart E., Evans E., Adams M., Mason M., et al. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine 2005, 23:2399-2402.